TCL Archive Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial October 26, 2012
TCL Archive Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival July 27, 2012